Eli Lilly and Company
LLY
$1,017.97
-$34.02-3.23%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 94.90% | 119.98% | 87.95% | 80.93% | 102.08% |
| Total Depreciation and Amortization | 13.02% | 13.60% | 17.33% | 16.84% | 15.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.98% | 3.07% | 186.76% | 258.78% | 249.83% |
| Change in Net Operating Assets | -50.32% | -4.90% | -42.17% | -40.78% | -76.24% |
| Cash from Operations | 90.67% | 166.28% | 142.55% | 153.51% | 107.97% |
| Capital Expenditure | -55.02% | -46.59% | -42.37% | -48.22% | -46.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 30.27% | 72.40% | 99.98% | 9.22% | 9.22% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.06% | 25.27% | -61.27% | -74.71% | -23.87% |
| Cash from Investing | -17.95% | 2.08% | -18.46% | -50.19% | -30.05% |
| Total Debt Issued | 15.33% | -17.76% | 2.53% | 2.53% | 31.99% |
| Total Debt Repaid | -103.34% | 62.70% | -10.32% | 122.66% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -64.32% | -943.31% | -- | -- | -233.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.04% | -14.93% | -14.99% | -15.06% | -15.01% |
| Other Financing Activities | -57.23% | -66.31% | -85.67% | -77.44% | -46.57% |
| Cash from Financing | -279.92% | -91.19% | -97.75% | 5.38% | -64.81% |
| Foreign Exchange rate Adjustments | 225.25% | -96.06% | 420.25% | -219.67% | -276.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 790.87% | 549.88% | -71.37% | 158.24% | -40.26% |